Certain studies have demonstrated beneficial outcomes; for instance, a pilot trial revealed that a probiotic cocktail comprising Lactobacilli, Bifidobacteria, and Streptococcus thermophilus resulted in a significant reduction (exceeding 20%) in serum ALT levels compared to the control group, suggesting a reduction in inflammation among MASH patients [125]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.